| HOME >> BIOLOGY >> TECHNOLOGY |
Trademarks
APTIMA, APTIMA COMBO 2, PACE, PROGENSA and TIGRIS are trademarks of Gen-Probe Incorporated. ULTRIO and PROCLEIX are trademarks of Chiron, a business unit of Novartis Vaccines and Diagnostics. All other trademarks are the property of their owners.
Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations, beliefs,
plans, objectives, assumptions or future events or performance, including
those under the heading "Updated 2008 Financial Guidance," are not
historical facts and are forward-looking statements. These statements are
often, but not always, made through the use of words or phrases such as
believe, will, expect, anticipate, estimate, intend, plan and would. For
example, statements concerning Gen-Probe's financial condition, possible or
expected results of operations, regulatory approvals, future milestone
payments, growth opportunities, and plans and objectives of management are
all forward-looking statements. Forward-looking statements are not
guarantees of performance. They involve known and unknown risks,
uncertainties and assumptions that may cause actual results, levels of
activity, performance or achievements to differ materially from those
expressed or implied. Some of these risks, uncertainties and assumptions
include but are not limited to: (i) the risk that we may not achieve our
expected 2008 growth, revenue, earnings or other financial targets, (ii)
the risk that we may not earn or receive milestone payments from our
collaborators, including Novartis, (iii) the possibility that the market
for the sale of our new products, such as our TIGRIS system, APTIMA Combo 2
assay, PROCLEIX ULTRIO assay and PROGENSA PCA3 assay, may not develop as
expected, (iv) the enhancement of existing products and the development of
new products, including products, if any, to be developed unde
'/>"/>
| SOURCE Gen-Probe Incorporated Copyright©2008 PR Newswire. All rights reserved |